1. Intra-arterial administration of methotrexate, Adriamycin, and cisplatin as neoadjuvant chemotherapy for bladder cancer

   • Manabu Kuriyama
   • Yoshito Takahashi
   • Yukimichi Kawada

   Session I: Local Administration Intra-Arterial Injection Pages: S1 - S4

2. Intra-arterial adriamycin chemotherapy in combination with radiotherapy for advanced bladder cancer

   • Yoshiteru Sumiyoshi
   • Takeshi Uyama
   • Susumu Kagawa

   Session I: Local Administration Intra-Arterial Injection Pages: S5 - S9

3. The 4th study of prophylactic intravesical chemotherapy with Adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese urological cancer research group of Adriamycin

   • Yosuke Matsumura
   • Hideyuki Akaza
   • the Japanese Urological Cancer Research Group for Adriamycin

   Intravesical Instillation I. Prophylactic Therapy Pages: S10 - S14

4. Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese urological cancer research group for Adriamycin

   • Hideyuki Akaza
   • Kenkichi Koiso
   • The Japanese Urological Cancer Research Group for Adriamycin

   Intravesical Instillation I. Prophylactic Therapy Pages: S15 - S20

5. Prophylactic chemotherapy for primary and recurrent superficial bladder cancer: preliminary results

   • Masaki Togashi
   • Nobuo Shinohara
   • The Hokkaido University Bladder Cancer Collaborating Group

   Intravesical Instillation I. Prophylactic Therapy Pages: S21 - S25

6. A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer-intravesical thio-TEPA versus oral UFT

   • Yoshihiko Hirao
   • Eigoro Okajima
   • Yoshio Maruyama

   Intravesical Instillation I. Prophylactic Therapy Pages: S26 - S30

7. Adjuvant chemotherapy with early intravesical instillation of Adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer

   • Toyofumi Ueda
   • Seiji Naito
   • the Kyushu University Urological Oncology Group

   Intravesical Instillation I. Prophylactic Therapy Pages: S31 - S36

8. Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response

   • Iwao Fukui
   • Kazunori Kihara
   • Hiroyuki Oshima

   Intravesical Instillation II. Ablative Therapy Pages: S37 - S40

9. Sequential instillation therapy with mitomycin C and Adriamycin for superficial bladder cancer

   • Shigeo Isaka
   • Tatsuya Okano
   • Jun Shimazaki

   Intravesical Instillation II. Ablative Therapy Pages: S41 - S44

10. Intravesical instillation of Adriamycin for bladder tumors

    • Hiroshi Ohe
    • Hiroki Watanabe
    • Shuichi Nakagawa

    OriginalPaper Pages: S45 - S49

11. Intravesical instillation of Adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study

    • Yoshitada Ohi
    • Hiroyuki Ohmori
    • Yasuo Ohashi

    Intravesical Instillation II. Ablative Therapy Pages: S50 - S54

12. Results of adjuvant chemotherapy for invasive uroepithelial cancer

    • Yasunari Uekado
    • Atsuyuki Hirano
    • Tadashi Ohkawa

    Session II: Systemic Administration Combination Chemotherapy (I) Pages: S55 - S58

13. Combination chemotherapy for advanced urothelial-tract carcinoma

    • Masafumi Sahashi
    • Yoshinari Ono
    • Masanori Fukushima

    Session II: Systemic Administration Combination Chemotherapy (I) Pages: S59 - S62

14. Use of methotrexate, vinblastine, adriamycin, and cisplatin in combination with radiation and hyperthermia as neo-adjuvant therapy for bladder cancer

    • Sumio Noguchi
    • Yoshinobu Kubota
    • Masahiko Hosaka

    Session II: Systemic Administration Combination Chemotherapy (I) Pages: S63 - S65

15. Clinical and pathological evaluations of methotrexate, vinblastine, Adriamycin and cisplatin chemotherapy for advanced urothelial cancers

    • Takayoshi Ogawa
    • Akinobu Gotoh
    • Sadao Kamidono

    Session II: Systemic Administration Combination Chemotherapy (I) Pages: S66 - S71

16. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer

    • Osamu Ueki
    • Haruo Hisazumi
    • Toshiaki Sugata

    Combination Chemotherapy (II) Pages: S72 - S76

17. Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin

    • Mikio Igawa
    • Taisuke Ohkuchi
    • Tsuguru Usui

    Combination Chemotherapy (II) Pages: S77 - S80

18. Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract — a preliminary report

    • Ming-Huei Lee
    • M. T. Chen
    • P. M. Chen

    Combination Chemotherapy (II) Pages: S81 - S84

19. Evaluation of systemic chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin for advanced bladder cancer

    • Toshihiko Kotake
    • Hideyuki Akaza
    • The Japanese Urological Cancer Research Group for Adriamycin

    Combination Chemotherapy (II) Pages: S85 - S89

20. The use of adriamycin and its derivatives in the treatment of prostatic cancer

    • D. W. W. Newling

    Session III: State of the Art in Urinary Tract Tumors Pages: S90 - S94

21. Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group

    • A. P. M. van der Meijden
    • Karl-Heinz Kurth
    • Members of the EORTC Genito-Urinary Group

    Session III: State of the Art in Urinary Tract Tumors Pages: S95 - S98

22. Chemotherapy of advanced transitional-cell carcinoma of the bladder

    • Robert S. Miller
    • Frank M. Torti

    Session III: State of the Art in Urinary Tract Tumors Pages: S99 - S110